BANTAM-01: A Multicenter, Open-Label, First-in-Human Phase 1 Dose Escalation and Expansion Study of 225Ac-GPC3 (BAY 3547926) in Patients with Advanced Hepatocellular Carcinoma.
Saved in:
| Title: | BANTAM-01: A Multicenter, Open-Label, First-in-Human Phase 1 Dose Escalation and Expansion Study of 225Ac-GPC3 (BAY 3547926) in Patients with Advanced Hepatocellular Carcinoma. |
|---|---|
| Authors: | Tjeertes, Jorrit1 (AUTHOR), Dostalek, Miroslav1 (AUTHOR), Glaus, Charles2 (AUTHOR), Gupta, Vinita2 (AUTHOR), Li, Daneng3 (AUTHOR), Nestler, Antje4 (AUTHOR), Pelekanou, Vasiliki2 (AUTHOR), Pinkert, Joerg4 (AUTHOR), Ratih, Ida5 (AUTHOR), Smith, Eric2 (AUTHOR), Subramanyam, Shyamal6 (AUTHOR), Vogel, Arndt7,8 (AUTHOR), Walker, Katrina5 (AUTHOR), Wilson Woods, Andrea9 (AUTHOR), Zimmermann, Stefan2 (AUTHOR), Junger, Henrik4,10 (AUTHOR) henrik.junger@bayer.com |
| Source: | Journal of Nuclear Medicine. Mar2026, Vol. 67 Issue 3, p360-365. 6p. |
| Database: | Engineering Source |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 01615505 |
|---|---|
| DOI: | 10.2967/jnumed.125.270814 |
